{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:58:51Z","timestamp":1764305931501,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.leukres.2022.106795","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T21:26:32Z","timestamp":1643923592000},"page":"106795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effects of conventional interventions on early-stage primary cutaneous marginal zone lymphoma: A population-based study"],"prefix":"10.1016","volume":"114","author":[{"given":"Hailing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106795_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12730","article-title":"Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site","volume":"165","author":"Khalil","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106795_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41379-019-0385-7","article-title":"Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals","volume":"33","author":"Jaffe","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.leukres.2022.106795_bib3","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106795_bib4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2005-04-1722","article-title":"Influence of antigen on the development of MALT lymphoma","volume":"107","author":"Lenze","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106795_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","article-title":"Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma","volume":"24","author":"Cerroni","year":"1997","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.leukres.2022.106795_bib6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106795_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification","volume":"143","author":"Senff","year":"2007","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.leukres.2022.106795_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2013.07.019","article-title":"Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC cancer agency experience","volume":"87","author":"Hamilton","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.leukres.2022.106795_bib9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00066-019-01541-7","article-title":"De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma","volume":"196","author":"Oertel","year":"2020","journal-title":"Trahlenther. Onkol."},{"key":"10.1016\/j.leukres.2022.106795_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.leukres.2022.106795_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.beha.2017.11.001","article-title":"Overview on the management of non-gastric MALT lymphomas","volume":"31","author":"Defrancesco","year":"2018","journal-title":"Best. Pract. Res Clin. Haematol."},{"key":"10.1016\/j.leukres.2022.106795_bib12","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases","volume":"155","author":"Kerl","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.leukres.2022.106795_bib13","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00277-018-3471-x","article-title":"Radiation therapy in indolent primary cutaneous B cell lymphoma: a single institute experience","volume":"97","author":"De Felice","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2022.106795_bib14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106795_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10238-017-0474-1","article-title":"Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue","volume":"18","author":"Kalogeropoulos","year":"2018","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.leukres.2022.106795_bib16","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1200\/JCO.2005.08.137","article-title":"The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry","volume":"23","author":"Smith","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106795_bib17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106795_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2022.106795_bib19","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ajh.25224","article-title":"Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management","volume":"93","author":"Wilcox","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106795_bib20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.leukres.2022.106795_bib21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","article-title":"Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab","volume":"77","author":"Kyrtsonis","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106795_bib22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.12484","article-title":"Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas","volume":"169","author":"Brandenburg","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.leukres.2022.106795_bib23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjd.18961","article-title":"Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience","volume":"183","author":"Hwang","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.leukres.2022.106795_bib24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2013.11.019","article-title":"Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa","volume":"70","author":"Vandersee","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.leukres.2022.106795_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjd.15071","article-title":"Primary cutaneous B-cell lymphoma: systemic spread is rare while cutaneous relapses and secondary malignancies are frequent","volume":"177","author":"Chan","year":"2017","journal-title":"Br. J. Dermatol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:13Z","timestamp":1758934933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":25,"alternative-id":["S0145212622000212"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106795","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of conventional interventions on early-stage primary cutaneous marginal zone lymphoma: A population-based study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106795"}}